Thomas Evers - Publications, H-index & Citations

Thomas Evers

Harvard Medical School

21H指数

108论文数

1.5K被引数

收录论文 42

发表时间

Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan (vol 14, 9095, 2024)在日本因心力衰竭住院的患者中开始和继续药物治疗 (第14卷，9095，2024)

SCIENTIFIC REPORTS

IF3.9

2024-10-15

OAAI

Okami, Suguru; Lecomte, Coralie; Raad, Hanaya; Aguila, Mireia; Mohrova, Zuzana; Takeichi, Makiko; Tsuchiya, Takanori; Ohlmeier, Christoph; Evers, Thomas; Michel, Alexander

Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan

SCIENTIFIC REPORTS

IF3.9

2024-04-20

OAAI

Okami, Suguru; Lecomte, Coralie; Raad, Hanaya; Aguila, Mireia; Mohrova, Zuzana; Takeichi, Makiko; Tsuchiya, Takanori; Ohlmeier, Christoph; Evers, Thomas; Michel, Alexander

Electronic health record characterization and outcomes of heart failure with preserved ejection fraction

AMERICAN HEART JOURNAL

IF3.5

2023-09-01

PREAI

Rao, Vishal N.; Cyr, Derek D.; Wruck, Lisa M.; Sanders, Gretchen; Hofmann, Paul; Roessig, Lothar; Siedentop, Harald; Evers, Thomas; Meyer, Michaela; Paraschin, Karen; Nkulikiyinka, Richard; Parikh, Kishan; Felker, G. Michael

Predictive Risk Models to Identify Patients at High-Risk for Severe Clinical Outcomes With Chronic Kidney Disease and Type 2 Diabetes 预测风险模型，以识别慢性肾病和2型糖尿病的严重临床结局高危患者

JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH

IF2.5

2022-01-22

OAAI

Sheer, Richard; Nair, Radhika; Pasquale, Margaret K.; Evers, Thomas; Cockrell, Meghan; Gay, Alain; Singh, Rakesh; Schmedt, Niklas

Adherence to Chronic Kidney Disease Screening Guidelines Among Patients With Type 2 Diabetes in a US Administrative Claims Database

MAYO CLINIC PROCEEDINGS

IF6.7

2021-04-01

OAAI

Folkerts, Kerstin; Petruski-Ivleva, Natalia; Comerford, Erin; Blankenburg, Michael; Evers, Thomas; Gay, Alain; Fried, Linda; Kovesdy, Csaba P.

Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model

clinical epidemiology

IF3.2

2020-06-01

OAAI

Lee, Moa P.; Glynn, Robert J.; Schneeweiss, Sebastian; Lin, Kueiyu Joshua; Patorno, Elisabetta; Barberio, Julie; Levin, Raisa; Evers, Thomas; Wang, Shirley, V; Desai, Rishi J.

RISK FACTORS FOR DECOMPENSATION AND CARDIOVASCULAR MORTALITY IN HEART FAILURE PATIENTS WITH REDUCED OR PRESERVED EJECTION FRACTION

VALUE IN HEALTH

IF6

2019-05-01

OAAI

Desai, R.; Lin, J.; Patorno, E.; Barberio, J.; Lee, M.; Levin, R.; Evers, T.; Wang, S., V; Schneeweiss, S.

HEALTHCARE RESOURCE UTILIZATION AND ACUTE COSTS IN FRENCH PATIENTS WITH CORONARY ARTERY DISEASE AND PERIPHERAL ARTERY DISEASE

VALUE IN HEALTH

IF6

2019-05-01

OAAI

Emery, C.; Torreton, E.; Oksen, D.; Briere, J. B.; Evers, T.; Fagnani, F.

HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH ABNORMAL POTASSIUM LEVELS AMONG US PATIENTS WITH SYSTOLIC AND DIASTOLIC HEART FAILURE: A POPULATION-BASED COHORT STUDY

VALUE IN HEALTH

IF6

2019-05-01

OAAI

Oksen, D.; Petruski-Ivleva, N.; Eapen, S.; Isaman, D.; Lewis, K.; Evers, T.

TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND COSTS OF CARE AMONG PATIENTS WITH NEWLY DIAGNOSED SYSTOLIC AND DIASTOLIC HEART FAILURE IN A US REAL-WORLD SETTING

VALUE IN HEALTH

IF6

2019-05-01

OAAI

Nguyen, C.; Zhang, X.; Evers, T.; Willey, V. J.; Tan, H.; Power, T. P.

Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES

IF6.7

2018-12-01

OAAI

Desai, Rishi J.; Lin, Kueiyu Joshua; Patorno, Elisabetta; Barberio, Julie; Lee, Moa; Levin, Raisa; Evers, Thomas; Wang, Shirley V.; Schneeweiss, Sebastian

USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RANDOMIZED CLINICAL TRIALS

VALUE IN HEALTH

IF6

2018-10-01

OAAI

Wang, S., V; Schneeweiss, S.; Gagne, J. J.; Evers, T.; Gerlinger, C.; Desai, R.; Najafzadeh, M.

Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2018-09-24

OAAI

Wang, Shirley, V; Schneeweiss, Sebastian; Gagne, Joshua J.; Evers, Thomas; Gerlinger, Christoph; Desai, Rishi; Najafzadeh, Mehdi

Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States 美国非瓣膜性心房颤动患者使用利伐沙班和达比加群预防卒中的药物依从性

INTERNATIONAL JOURNAL OF CARDIOLOGY

IF3.2

2016-06-01

PREAI

Coleman, Craig I.; Tangirala, Muralikrishna; Evers, Thomas

Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation

EUROPACE

IF7.4

2016-01-31

125

OAAI

Beyer-Westendorf, Jan; Ehlken, Birgit; Evers, Thomas

REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation - The RELIEF study

INTERNATIONAL JOURNAL OF CARDIOLOGY

IF3.2

2016-01-01

OAAI

Coleman, Craig I.; Antz, Matthias; Ehlken, Birgit; Evers, Thomas

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial

EUROPACE

IF7.4

2015-10-20

OAAI

Hohnloser, Stefan H.; Cappato, Riccardo; Ezekowitz, Michael D.; Evers, Thomas; Sahin, Kurtulus; Kirchhof, Paulus; Meng, Isabelle Ling; van Eickels, Martin; Camm, A. John

FACTORS INFLUENCING MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN CANADA AND SWEDEN

VALUE IN HEALTH

IF6

2014-05-01

OAAI

Lara, N.; Evers, T.; Levac, B.; Fraschke, A.; Pedros, M.

CLINICAL IMPACT OF TREATMENT PERSISTENCE IN PATIENTS WITH ATRIAL FIBRILLATION

VALUE IN HEALTH

IF6

2013-05-01

OAAI

Evers, T.; Diamantopoulos, A.